The effects of carrier nature and pH on rhBMP-2-induced ectopic bone formation

Journal of Controlled Release

Volumn 147, Issue 1, 2010, Pages 38-44

  Luca, Ludmila ^a   Rougemont, Anne Laure ^b   Walpoth, Beat H ^c   Gurny, Robert ^a   Jordan, Olivier ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Bioactivity; BMP 2; Chitosan hydrogel; Ectopic bone formation; Formulation pH; Hyaluronan hydrogel

Indexed keywords

BMP-2; CHITOSAN HYDROGEL; ECTOPIC BONES; FORMULATION PH; HYALURONAN HYDROGELS;

ANIMALS; BIOACTIVITY; BIOPOLYMERS; BONE; CHITIN; CHITOSAN; COMPUTERIZED TOMOGRAPHY; HYDROGELS; MUSCLE;

PH EFFECTS;

CHITOSAN; HYALURONIC ACID; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE MINERALIZATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG FORMULATION; HISTOLOGY; HYDROGEL; MALE; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; OSSIFICATION; PH MEASUREMENT; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; RAT;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE MORPHOGENETIC PROTEIN 2; BONE REGENERATION; BONE SUBSTITUTES; CHITOSAN; DRUG CARRIERS; HYALURONIC ACID; HYDROGELS; HYDROGEN-ION CONCENTRATION; INJECTIONS, INTRAMUSCULAR; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS;

EID: 78649583169     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.06.011     Document Type: Article

References (36)

1. Gautschi O.P., Frey S.P., Zellweger R. Bone morphogenetic proteins in clinical applications. ANZ J. Surg. 2007, 77:626-631.
2. Hollinger J.O., Uludag H., Winn S.R. Sustained release emphasizing recombinant human bone morphogenetic protein-2. Adv. Drug Deliv. Rev. 1998, 31:303-318.
3. Seeherman H., Wozney J., Li R. Bone morphogenetic protein delivery systems. Spine (Phila Pa 1976.) 2002, 27:S16-S23.
4. Seeherman H., Wozney J.M. Delivery of bone morphogenetic proteins for orthopedic tissue regeneration. Cytokine Growth Factor Rev. 2005, 16:329-345.
5. Li R.H., Wozney J.M. Delivering on the promise of bone morphogenetic proteins. Trends Biotechnol. 2001, 19:255-265.
6. McKay W.F., Peckham S.M., Badura J.M. A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE Bone Graft). Int. Orthop. 2007, 31:729-734.
7. Geiger M., Li R.H., Friess W. Collagen sponges for bone regeneration with rhBMP-2. Adv. Drug Deliv. Rev. 2003, 55:1613-1629.
8. Boraiah S., Paul O., Hawkes D., Wickham M., Lorich D.G. Complications of recombinant human BMP-2 for treating complex tibial plateau fractures: a preliminary report. Clin. Orthop. Relat. Res. 2009, 467:3257-3262.
9. Joseph V., Rampersaud Y.R. Heterotopic bone formation with the use of rhBMP2 in posterior minimal access interbody fusion: a CT analysis. Spine (Phila Pa 1976.) 2007, 32:2885-2890.
10. Crawford C.H., Carreon L.Y., McGinnis M.D., Campbell M.J., Glassman S.D. Perioperative complications of recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge versus iliac crest bone graft for posterior cervical arthrodesis. Spine (Phila Pa 1976.) 2009, 34:1390-1394.
11. Shields L.B., Raque G.H., Glassman S.D., Campbell M., Vitaz T., Harpring J., Shields C.B. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine (Phila Pa 1976.) 2006, 31:542-547.
12. Carlisle E., Fischgrund J.S. Bone morphogenetic proteins for spinal fusion. Spine J. 2005, 5:240S-249S.
13. Silva A.K., Richard C., Bessodes M., Scherman D., Merten O.W. Growth Factor Delivery Approaches in Hydrogels. Biomacromolecules 2008, 10(1):9-18.
14. Kretlow J.D., Klouda L., Mikos A.G. Injectable matrices and scaffolds for drug delivery in tissue engineering. Adv. Drug Deliv. Rev. 2007, 59:263-273.
15. Gutowska A., Jeong B., Jasionowski M. Injectable gels for tissue engineering. Anat. Rec. 2001, 263:342-349.
16. Bessa P.C., Casal M., Reis R.L. Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). J. Tissue Eng. Regen. Med. 2008, 2:81-96.
17. Schuetz Y.B., Gurny R., Jordan O. A novel thermoresponsive hydrogel based on chitosan. Eur. J. Pharm. Biopharm. 2008, 68:19-25.
18. Patois E., Cruz S.O., Tille J.C., Walpoth B., Gurny R., Jordan O. Novel thermosensitive chitosan hydrogels: in vivo evaluation. J. Biomed. Mater. Res. A 2008, 91A:324-330.
19. Berger J., Reist M., Mayer J.M., Felt O., Gurny R. Structure and interactions in chitosan hydrogels formed by complexation or aggregation for biomedical applications. Eur. J. Pharm. Biopharm. 2004, 57:35-52.
20. Kim H.D., Valentini R.F. Retention and activity of BMP-2 in hyaluronic acid-based scaffolds in vitro. J. Biomed. Mater. Res. 2002, 59:573-584.
21. Bulpitt P., Aeschlimann D. New strategy for chemical modification of hyaluronic acid: preparation of functionalized derivatives and their use in the formation of novel biocompatible hydrogels. J. Biomed. Mater. Res. 1999, 47:152-169.
22. Luca L., Capelle M.A., Machaidze G., Arvinte T., Jordan O., Gurny R. Physical instability, aggregation and conformational changes of recombinant human bone morphogenetic protein-2 (rhBMP-2). Int. J. Pharm. 2010, 391:48-54.
23. Friess W., Uludag H., Foskett S., Biron R. Bone regeneration with recombinant human bone morphogenetic protein-2 (rhBMP-2) using absorbable collagen sponges (ACS): influence of processing on ACS characteristics and formulation. Pharm. Dev. Technol. 1999, 4:387-396.
24. Berger J., Reist M., Chenite A., Felt-Baeyens O., Mayer J.M., Gurny R. Pseudo-thermosetting chitosan hydrogels for biomedical application. Int. J. Pharm. 2005, 288:197-206.
25. Lavertu M., Xia Z., Serreqi A.N., Berrada M., Rodrigues A., Wang D., Buschmann M.D., Gupta A. A validated 1H NMR method for the determination of the degree of deacetylation of chitosan. J. Pharm. Biomed. Anal. 2003, 32:1149-1158.
26. Bergman K., Engstrand T., Hilborn J., Ossipov D., Piskounova S., Bowden T. Injectable cell-free template for bone-tissue formation. J. Biomed. Mater. Res. A 2008, 91:1111-1118.
27. Uludag H., D'Augusta D., Golden J., Li J., Timony G., Riedel R., Wozney J.M. Implantation of recombinant human bone morphogenetic proteins with biomaterial carriers: a correlation between protein pharmacokinetics and osteoinduction in the rat ectopic model. J. Biomed. Mater. Res. 2000, 50:227-238.
28. Uludag H., D'Augusta D., Palmer R., Timony G., Wozney J. Characterization of rhBMP-2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model. J. Biomed. Mater. Res. 1999, 46:193-202.
29. Uludag H., Gao T., Porter T.J., Friess W., Wozney J.M. Delivery systems for BMPs: factors contributing to protein retention at an application site. J. Bone Joint Surg. Am. 2001, 83-A(Suppl 1):S128-S135.
30. Kempen D.H., Lu L., Hefferan T.E., Creemers L.B., Maran A., Classic K.L., Dhert W.J., Yaszemski M.J. Retention of in vitro and in vivo BMP-2 bioactivities in sustained delivery vehicles for bone tissue engineering. Biomaterials 2008, 29:3245-3252.
31. Seeherman H., Li R., Wozney J. A review of preclinical program development for evaluating injectable carriers for osteogenic factors. J. Bone Joint Surg. Am. 2003, 85-A(Suppl 3):96-108.
32. Seeherman H. The influence of delivery vehicles and their properties on the repair of segmental defects and fractures with osteogenic factors. J. Bone Joint Surg. Am. 2001, 83-A(Suppl 1):S79-S81.
33. Oliveira S.M., Mijares D.Q., Turner G., Amaral I.F., Barbosa M.A., Teixeira C.C. Engineering endochondral bone: in vivo studies. Tissue Eng. A 2009, 15:635-643.
34. Reddi A.H., Anderson W.A. Collagenous bone matrix-induced endochondral ossification hemopoiesis. J. Cell Biol. 1976, 69:557-572.
35. Santavirta S., Konttinen Y.T., Nordstrom D., Makela A., Sorsa T., Hukkanen M., Rokkanen P. Immunologic studies of nonunited fractures. Acta Orthop. Scand. 1992, 63:579-586.
36. Andrew J.G., Andrew S.M., Freemont A.J., Marsh D.R. Inflammatory cells in normal human fracture healing. Acta Orthop. Scand. 1994, 65:462-466.